Cognition Therapeutics, Inc. announced the publication of a manuscript in the American Chemical Society journal Organic Process Research & Development, detailing a novel chemical process for manufacturing zervimesine (CT1812). This new process is designed to enhance the room temperature stability of the lead Alzheimer’s candidate.
The development of this advanced manufacturing process is a critical step towards ensuring the scalability and reliability of zervimesine supply for future clinical trials and potential commercialization. Provisional patent applications have been filed to protect this innovation.
This operational advancement supports the company's strategic goal of advancing zervimesine into late-stage clinical development for neurodegenerative disorders. The enhanced stability could also contribute to more efficient storage and distribution of the drug.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.